Brind.
  1. Mesoblast announced it is seeking accelerated approval in the US via a BLA filing with the FDA.
  2. Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.

FDA Approves New Potency Assay for Mesoblast's Ryoncil® Product

1 report, 1 independent Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The United States Food and Drug Administration approved the T-cell Proliferation Inhibition BioAssay (TIBA) for Mesoblast's product lots. This assay is used for release and stability monitoring of Ryoncil®, Mesoblast's mesenchymal stromal cell product. The TIBA assay will be used alongside existing potency assays to ensure the product remains consistent and potent during manufacturing changes or production in new facilities.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The approval of the TIBA assay supports the continued commercial use of Ryoncil®, which is the first industrially-manufactured allogeneic MSC product approved by the FDA for any indication. This regulatory alignment between Mesoblast and the FDA is critical for the product's market availability.

Mesoblast is currently seeking FDA review of the Biologics License Application for its product rexlemestrocel-L and has announced plans to seek accelerated approval in the US.

From manilatimes.net

Who's involved

  • FDARegulatory agency that approved the new potency assay for the product lots.
  • MesoblastPharmaceutical company whose product Ryoncil® received the assay approval.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • MesoblastSpeculative

    Mesoblast might see improved supply chain stability and reduced costs associated with quality control for Ryoncil®.

  • State Street CorporationSpeculative

    State Street Corporation might see increased value in its equity stake in Mesoblast due to positive regulatory news.

  • Australian Securities ExchangeSpeculative

    Australian Securities Exchange may see increased investor confidence, potentially driving up the stock price of Mesoblast.

  • NasdaqSpeculative

    Nasdaq may see increased investor confidence, potentially driving up the stock price of Mesoblast.

Keep exploring

Part of

Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L. All 1 developments

Within Mesoblast announced it is seeking accelerated approval in the US via a BLA filing with the FDA.

The entities involved

Related events

Coverage

Newest first; wire copies grouped